Results 191 to 200 of about 1,139,517 (313)

Editorial: Advancements in protein modification for enhanced digestibility. [PDF]

Front Nutr
Shokri S, Jarpa-Parra M.
europepmc   +1 more source

Multiphase Kinetic Modeling of Air Pollutant Effects on Protein Modification and Nitrotyrosine Formation in Epithelial Lining Fluid. [PDF]

Environ Sci Technol, 2023
Mishra A, Lelieveld S, Pöschl U, Berkemeier T.   +3 more
europepmc   +1 more source

Modification of Proteins [PDF]

, 1982
openaire   +1 more source

Genotoxic stresses and protein modifications [PDF]

Journal of Molecular Cell Biology, 2012
openaire   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Correction to: CHD1L prevents lipopolysaccharide-induced hepatocellular carcinomar cell death by activating hnRNP A2/B1-nmMYLK axis

Cell Death and Disease, 2022
Guangliang Wang, Xiaofeng Zhang, Wei Cheng, Yanxuan Mo, Juan Chen, Zhiming Cao, Xiaogang Chen, Huiqin Cui, Shanshan Liu, Li Huang, Ming Liu, Lei Ma, Ning-Fang Ma   +12 more
doaj   +1 more source

Protein modification by a eukaryotic-like ubiquitin-related modifier in the hyperthermophilic archaeon <i>Saccharolobus islandicus</i>. [PDF]

mSystems
Cao J, Xiong D, Zheng X, Yuan W, Huang L.   +4 more
europepmc   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Peroxynitrite-Activated Conditional Chemical Probe for the Affinity-Based Protein Modification. [PDF]

Anal Chem
Wu CC, Lee SH, Huang TJ, Lin JC, Lu YH, Wu SP, Tan KT.   +6 more
europepmc   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source